Related references
Note: Only part of the references are listed.Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2-advanced breast cancer treated with ribociclib plus endocrine therapy vs physician's choice combination chemotherapy
Yen-Shen Lu et al.
CANCER RESEARCH (2023)
EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
Aditya Bardia et al.
CANCER RESEARCH (2023)
The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology
Kelly A. Hirko et al.
BMC MEDICINE (2022)
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Yen-Shen Lu et al.
CLINICAL CANCER RESEARCH (2022)
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Gabriel N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)
M. P. Goetz et al.
ANNALS OF ONCOLOGY (2022)
Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2022)
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)
Sung Hoon Sim et al.
BREAST (2022)
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
Xiaoping Ma et al.
ANNALS OF MEDICINE (2022)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy
Madeline M. Cook et al.
ONCOLOGIST (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
F. Andre et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2-advanced breast cancer: MONARCH 2 & 3 trials
Masakazu Toi et al.
CANCER SCIENCE (2021)
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Binghe Xu et al.
NATURE MEDICINE (2021)
Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study
Chao Li et al.
CANCER MEDICINE (2021)
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Eva Maria Ciruelos et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo et al.
LANCET ONCOLOGY (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
Kenichi Inoue et al.
BREAST CANCER (2021)
Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
Kyung-Hun Lee et al.
CANCER RESEARCH AND TREATMENT (2021)
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2021)
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Munawar Anwar et al.
CLINICAL CANCER RESEARCH (2021)
Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.
Zhongyu Yuan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
Stephen Johnston et al.
NPJ BREAST CANCER (2021)
Breast Cancer Statistics in Korea, 2018
Sang Yull Kang et al.
JOURNAL OF BREAST CANCER (2021)
Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
Feng Li et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?
Adam S. Komorowski et al.
CLINICAL BREAST CANCER (2020)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
Takayoshi Uematsu et al.
BREAST CANCER (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J. Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
Tatsunori Shimoi et al.
BREAST CANCER (2020)
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
Seock-Ah Im et al.
SCIENTIFIC REPORTS (2020)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone
Michael Kosmin et al.
RADIOLOGY (2020)
Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
Xinyu Gui et al.
ONCOLOGY LETTERS (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population
M. Kanai et al.
ANNALS OF ONCOLOGY (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
Nadia Harbeck et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population
Ching-Hung Lin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Insights Into Breast Cancer in the East vs the West: A Review
Yoon-Sim Yap et al.
JAMA ONCOLOGY (2019)
Treating HR+/HER2-breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
Winnie Yeo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
Mark Robson et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Mario Giuliano et al.
LANCET ONCOLOGY (2019)
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis
Kirsty Wai Chung Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
Malgorzata Szostakowska et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park et al.
LANCET ONCOLOGY (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D. A. Yardley et al.
ANNALS OF ONCOLOGY (2018)
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
Atilla Soran et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Triple negative breast cancer in Asia: An insider's view
Chao Wang et al.
CANCER TREATMENT REVIEWS (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
被撤回的出版物: Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE (Retracted article. See vol. 39, pg. 95, 2021)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
Rashmi Murthy et al.
LANCET ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer The BOLERO-6 Randomized Clinical Trial
Guy Jerusalem et al.
JAMA ONCOLOGY (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
Mothaffar Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Current Treatment Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer: An Indian Perspective
Gupta Sudeep et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2018)
Practical consensus recommendations on management of triple-negative metastatic breast cancer
R. Rangarao et al.
SOUTH ASIAN JOURNAL OF CANCER (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The global burden of women's cancers: a grand challenge in global health
Ophira Ginsburg et al.
LANCET (2017)
Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer
Steven Narod et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Epidemiology of breast cancer in Indian women
Shreshtha Malvia et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer
Melissa K. Accordino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response
Christoph I. Lee et al.
BREAST (2015)
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
Xi-Chun Hu et al.
LANCET ONCOLOGY (2015)
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
Rajendra Badwe et al.
LANCET ONCOLOGY (2015)
Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting
Nirmala Bhoo-Pathy et al.
SCIENTIFIC REPORTS (2015)
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
Jian Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M. Piccart et al.
ANNALS OF ONCOLOGY (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
Yeon Hee Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
Jungsil Ro et al.
BMC CANCER (2012)
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Breast cancer in a multi-ethnic Asian setting: Results from the Singapore-Malaysia hospital-based breast cancer registry
Nirmala Bhoo Pathy et al.
BREAST (2011)
Spinal Instability Neoplastic Score: An Analysis of Reliability and Validity From the Spine Oncology Study Group
Daryl R. Fourney et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Alessandra Gennari et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Adam M. Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
Bing-He Xu et al.
Chinese Journal of Cancer (2011)
Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival
Jung Ah Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
William F. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
Martine J. Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
CA Dykewicz
CLINICAL INFECTIOUS DISEASES (2001)
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
JGM Klijn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
